Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on June 2, 2025
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
GlobeNewswire
·
June 2, 2025
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing …
Ambiq Names Jeff Winzeler as Chief Financial Officer
GlobeNewswire
·
June 2, 2025
AUSTIN, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Ambiq®, a technology leader in ultra-low-power semiconductor solutions for edge AI, is pleased to announce Jeff Winzeler as Ambiq’s new Chief Financial Officer (CFO). Jeff Winzeler brings extensive CFO and …
AITX's RAD Receives RIO™ Expansion Orders from Major Client
GlobeNewswire
·
June 2, 2025
Latest Orders Part of Ongoing National Rollout of AI-Powered Security Solutions by Leading Logistics Provider Detroit, Michigan, June 02, 2025 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), a global …
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
GlobeNewswire
·
June 2, 2025
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dyadic is well positioned to seize on geopolitical …
Catalyst Continues Growth with Hirings of Institutional Relations and Portfolio Strategist Professionals
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Capital Advisors LLC, a leading provider of alternative and innovative investment solutions, today announced the hire of Robert Gallant, CFA, CAIA, as Executive Director of Institutional Relations, and …
Syncromune® Inc. Presents Positive Results from SYNC-T® Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025
GlobeNewswire
·
June 2, 2025
Presentation highlights deep and durable responses and radiographic resolution of bone metastases in patients with advanced prostate cancer Final clinical data demonstrate an 87% overall response rate in patients with metastatic prostate cancer Results …
TELA Bio Appoints Jeffrey Blizard as President
GlobeNewswire
·
June 2, 2025
MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President …
Rakovina Therapeutics Announces 2025 Q1 Financial Results and Provides Corporate Update
GlobeNewswire
·
June 2, 2025
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing novel DNA-damage response (DDR) cancer therapies powered by artificial …
TruGolf Announces Listing Extension from Nasdaq
GlobeNewswire
·
June 2, 2025
Salt Lake City, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, today announced that the Nasdaq Hearings Panel has granted the company an extension of time to comply with Nasdaq listing …
NewGen Announces Planned $30 Million Strategic Investment in Solana Digital Asset Staking
GlobeNewswire
·
June 2, 2025
BANGKOK, June 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced plans …
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE …
IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
GlobeNewswire
·
June 2, 2025
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, …
Joint Press Release of Constellation Software Inc. and Topicus.com Inc. -- Topicus.com Inc. completes acquisition of Cipal Schaubroeck in Belgium
GlobeNewswire
·
June 2, 2025
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus’ subsidiary Total Specific Solutions (TSS) B.V. (“TSS”) has completed the sale and transfer of all issued and …
Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer
GlobeNewswire
·
June 2, 2025
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly …
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewswire
·
June 2, 2025
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines …
SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients
GlobeNewswire
·
June 2, 2025
Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic biotechnology company, today announced the closing of a $ …
Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
GlobeNewswire
·
June 2, 2025
Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes preclinical package for Investigational New Drug submission in mid-2025 with Phase 1 therapeutic study initiation expected in 4Q25 …
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
GlobeNewswire
·
June 2, 2025
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
GlobeNewswire
·
June 2, 2025
-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of …
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …